Overview
This three-component blend adds AOD-9604 to the standard CJC-1295 plus ipamorelin GH-axis pairing.
AOD-9604 is a fragment of human growth hormone corresponding to amino acids 177–191, the C-terminal region associated with the hormone's lipolytic activity. Its design premise is separation of function: the fragment was intended to retain fat-mobilising effects without the growth-promoting and glucose-affecting actions of the full hormone.
There is an obvious tension in this particular combination that vendors do not usually address. AOD-9604's entire rationale is obtaining lipolytic effect without the systemic GH signal — yet it is blended here with two compounds whose purpose is to raise endogenous GH. If the systemic GH signal is desirable enough to stimulate deliberately, the argument for a fragment specifically designed to avoid it becomes unclear.
No study of this three-way combination was located, and AOD-9604's own clinical record for fat loss is unimpressive. See our individual AOD-9604, CJC-1295 and ipamorelin entries.
What the evidence shows
Separated by study type- HumanClinical trials and human studies
- No trials of this combination. AOD-9604's individual clinical fat-loss record is weak.
- AnimalRodent and other animal models
- No studies of the combination located.
- In vitroCell and tissue studies
- No studies of the combination located.
Key studies & findings
1 study- 1
No study of this three-component combination was located.
Benefits & effects
1 documentedCombines GH-axis stimulation with a fragment associated with lipolysis
Side effects & safety
2 reportedSafety noteCompounded blend of research compounds for laboratory use only. Premixed blends compound the unknowns of each component and add one of their own: if an adverse effect occurs, the responsible component cannot be identified.
Recorded in the cited literature No safety data for the combination.
Adverse effects cannot be attributed to a specific component
Elevated GH and IGF-1 carry their own risks
Limitations & open questions
This is a fixed-ratio premixed combination, and that carries specific consequences beyond those of its individual components. The components cannot be titrated independently — adjusting one means adjusting all of them. If a reaction occurs, attribution is impossible. And the combination itself has not been studied: evidence for the individual compounds does not transfer to the mixture, because combined pharmacology is not the sum of separate pharmacologies. Blends are a convenience and pricing format, not a validated pharmacological unit. There is also an internal tension specific to this blend: AOD-9604 exists to deliver lipolytic effects without a systemic GH signal, while the other two components exist to raise systemic GH. The rationale for combining them is not well articulated, and no study tests it.
Pharmacology
A mixture rather than a single chemical entity. Component ratios vary between compounders. See the individual entries for component chemistry.
Frequently asked questions
What does AOD-9604 add to a GH blend?
It is the hGH 177–191 fragment associated with fat mobilisation. The stated rationale is added lipolytic effect. Whether it adds anything on top of raised endogenous GH has not been tested.
Isn't there a contradiction in this blend?
Yes, and it is worth noticing. AOD-9604 was designed to give lipolytic effects *without* the systemic GH signal. Here it is combined with two compounds whose job is to raise that signal. Vendors rarely explain this.